Cannabist Company Holdings (CBST) AI Stock Analysis

• Market Cap: $227.80M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.00
• Revenue Growth: -21.73%
• EPS Growth: 4.03%
• Country: CA
• Employees: 1,681
• Sector: Healthcare
• Sector Strength: 54
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.22
• Shares Outstanding: 491,745,330
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $0.50
• Price Target Upside: -11.59% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: C$0.50 ▼(-10.71% Downside)

The overall stock score of 44 reflects significant financial challenges, including declining revenues, high debt, and negative cash flows. While there are some operational improvements noted in the earnings call, the technical analysis indicates a lack of momentum and potential overbought conditions. The negative P/E ratio and lack of dividend yield further weigh down the valuation.

Positive Factors

Expansion and Acquisitions

Verano set to expand operations in Arizona and enter Virginia via acquisitions with The Cannabist Co.

Financial Benefit

The transaction terms indicate potential financial benefit for CBST through cash and voting shares.

Negative Factors

Asset Dispositions

CBST progresses on previously announced planned asset dispositions.

Cannabist Company Holdings Business Overview & Revenue Model

Company Description

The Cannabist Company Holdings Inc. engages in the cultivation, manufacture, and provision of cannabis products and related services in the United States and internationally. The company offers spanning flower, edibles, oils, and tablets under the Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber brand names. It holds licenses in 17 jurisdictions in the United States. The company was formerly known as Columbia Care Inc. and changed its name to The Cannabist Company Holdings Inc. in September 2023. The company was founded in 2012 and is headquartered in New York, New York.

How the Company Makes Money

Cannabist Company Holdings generates revenue through several key streams. Primarily, the company earns money from the sale of cannabis products across its retail outlets and through wholesale distribution to other businesses. CBST also leverages strategic partnerships with other cannabis brands and companies to enhance its product offerings and market reach. Additionally, the company may generate income through licensing agreements, allowing other businesses to produce and sell products under its brand name. The company's revenue is significantly influenced by the regulatory environment and consumer demand within the legal cannabis market.

Cannabist Company Holdings Financial Statement Overview

Summary

Cannabist Company Holdings faces significant financial challenges across all verticals. The income statement shows declining revenues and persistent losses, while the balance sheet is burdened with high debt and negative equity. Cash flow issues further exacerbate the situation, with negative operating and free cash flows. The company needs to address these financial weaknesses to improve its financial health and stability.

Income Statement

The income statement reveals significant challenges, with declining revenue growth at -9.17% TTM and negative net profit margins consistently over the years. The gross profit margin has slightly decreased to 35.03% TTM, indicating some pressure on profitability. The company has struggled with negative EBIT and EBITDA margins, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial structure with a negative stockholders' equity of -$137.97 million TTM, leading to an unsustainable debt-to-equity ratio of -7.66. The return on equity is positive at 10.11% TTM, but this is due to the negative equity, which is not a healthy sign. The equity ratio is negative, indicating liabilities exceed assets.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow, with a declining free cash flow growth rate of -18.86% TTM. The operating cash flow to net income ratio is negative, suggesting cash flow issues. However, the free cash flow to net income ratio is above 1, indicating some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	384.71M	458.72M	511.33M	491.31M	456.03M	188.99M
Gross Profit	124.15M	168.30M	179.97M	136.13M	146.92M	52.68M
EBITDA	-15.44M	28.61M	-51.30M	-282.36M	-63.14M	-115.66M
Net Income	-166.56M	-105.89M	-175.71M	-399.52M	-141.84M	-100.85M
Balance Sheet
Total Assets	563.84M	696.17M	823.11M	994.28M	1.37B	727.53M
Cash, Cash Equivalents and Short-Term Investments	15.46M	33.61M	36.91M	48.13M	82.09M	61.11M
Total Debt	444.50M	478.42M	546.32M	566.97M	420.75M	295.21M
Total Liabilities	702.68M	726.23M	757.76M	787.47M	824.57M	440.58M
Stockholders Equity	-137.97M	-28.69M	66.53M	213.19M	570.62M	306.82M
Cash Flow
Free Cash Flow	-31.85M	-29.21M	-2.50M	-179.70M	-132.64M	-97.42M
Operating Cash Flow	-24.79M	-23.38M	7.47M	-106.99M	-518.40K	-52.27M
Investing Cash Flow	36.06M	30.98M	-3.50M	-72.34M	-189.67M	-24.02M
Financing Cash Flow	-18.58M	-9.00M	-14.12M	147.59M	200.66M	90.00M

Cannabist Company Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.56
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CBST, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.56, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CBST.

Cannabist Company Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.84B	-0.18	-41.53%	2.28%	22.72%	-1.87%
CBST	44 Neutral	$227.80M	―	-554.70%	―	-21.73%	4.03%
CGC	―	$471.42M	―	-98.42%	―	―	―
OGI	―	$229.89M	121.83	1.86%	―	―	―
ACB	―	$303.86M	97.05	-0.70%	―	―	―
CBWTF	―	$149.63M	7.25	22.40%	―	―	―
TSND	54 Neutral	C$580.48M	―	-45.36%	―	-12.25%	-47.36%

Cannabist Company Holdings Corporate Events

Cannabist Company Reports Q2 2025 Results Amid Strategic Restructuring

The Cannabist Company reported a challenging second quarter of 2025, with a slight decline in revenue and gross margin due to strategic divestitures and inventory adjustments. Despite these challenges, the company made significant progress in restructuring its debt and optimizing its operational footprint, including the sale of retail locations and the launch of adult-use cannabis sales in Delaware. The company remains focused on managing liquidity and enhancing its product offerings, with plans to open new retail locations in Ohio.

The most recent analyst rating on (TSE:CBST) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.

The Cannabist Company Launches Adult-Use Cannabis Sales in Delaware

The Cannabist Company has launched adult-use cannabis sales in Delaware, expanding its market presence with three Columbia Care dispensaries strategically located across the state. The company’s cultivation facility in Milford and its portfolio of premium cannabis products, including house brands and brand partner Ric Flair Drip, are now available to adult consumers. This expansion is expected to enhance the company’s operations and strengthen its position in the cannabis industry, providing new opportunities for growth and engagement with Delaware communities.

The most recent analyst rating on (TSE:CBST) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.

The Cannabist Company to Announce Q2 2025 Financial Results

The Cannabist Company announced it will release its second-quarter 2025 financial results on August 7, 2025, before U.S. markets open, followed by a conference call. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially influencing its market position and investor confidence.

The most recent analyst rating on (TSE:CBST) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.

The Cannabist Company Completes Strategic Financial Restructuring

The Cannabist Company Holdings Inc. has successfully completed a court-approved plan of arrangement, which involved exchanging existing senior secured notes for new senior notes due in 2028 and issuing new common shares and warrants to stakeholders. This strategic financial restructuring aims to enhance the company’s financial stability and operational flexibility, potentially strengthening its market position in the competitive cannabis industry.

The most recent analyst rating on (TSE:CBST) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.

Cannabist Company Receives Court Approval for Strategic Arrangement

The Cannabist Company Holdings Inc. announced it has received court approval for its previously announced plan of arrangement under the Canada Business Corporations Act. This approval marks a significant step forward for the company, with the closing date targeted for May 29, 2025, pending regulatory approvals. The arrangement involves the issuance of new warrants to shareholders and is expected to impact the company’s operational structure and market positioning, enhancing its ability to deliver products and services across its network.

The most recent analyst rating on (TSE:CBST) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.